TRCT
NUVB icon

Tower Research Capital (TRC)’s Nuvation Bio NUVB Stock Holding History

Tower Research Capital (TRC)’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.3K Sell
16,780
-3,029
-15% -$14.8K ﹤0.01% 2218
2026
Q1 		$85K Buy
19,809
+2,757
+16% +$15.4K ﹤0.01% 2318
2025
Q4 		$153K Buy
17,052
+9,569
+128% +$59.3K ﹤0.01% 1643
2025
Q3 		$27.7K Sell
7,483
-19,975
-73% -$54.4K ﹤0.01% 3019
2025
Q2 		$53.5K Buy
27,458
+20,244
+281% +$42.2K ﹤0.01% 2918
2025
Q1 		$12.7K Buy
7,214
+2,908
+68% +$6.62K ﹤0.01% 3428
2024
Q4 		$11.5K Sell
4,306
-3,992
-48% -$10.3K ﹤0.01% 3713
2024
Q3 		$19K Sell
8,298
-11,575
-58% -$35.3K ﹤0.01% 3265
2024
Q2 		$58K Buy
19,873
+3,159
+19% +$9.64K ﹤0.01% 2983
2024
Q1 		$60.8K Buy
16,714
+8,139
+95% +$15.6K ﹤0.01% 2144
2023
Q4 		$12.9K Sell
8,575
-3,641
-30% -$4.69K ﹤0.01% 3998
2023
Q3 		$16.4K Buy
12,216
+8,856
+264% +$14.7K ﹤0.01% 3562
2023
Q2 		$6.05K Sell
3,360
-30,910
-90% -$52.5K ﹤0.01% 4746
2023
Q1 		$57K Buy
34,270
+24,315
+244% +$49.3K ﹤0.01% 2378
2022
Q4 		$19K Buy
9,955
+1,199
+14% +$2.43K ﹤0.01% 3180
2022
Q3 		$20K Sell
8,756
-646
-7% -$1.84K ﹤0.01% 3938
2022
Q2 		$30K Buy
9,402
+8,164
+659% +$35.6K ﹤0.01% 3382
2022
Q1 		$7K Sell
1,238
-1,350
-52% -$7.58K ﹤0.01% 4742
2021
Q4 		$22K Sell
2,588
-1,110
-30% -$10.2K ﹤0.01% 3564
2021
Q3 		$37K Buy
3,698
+2,913
+371% +$26.4K ﹤0.01% 3200
2021
Q2 		$7K Buy
785
+110
+16% +$1.25K ﹤0.01% 4561
2021
Q1 		$7K Sell
675
-641
-49% -$7.17K ﹤0.01% 4542
2020
Q4 		$15K Buy
+1,316
New +$13.7K ﹤0.01% 4050

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Tower Research Capital (TRC)'s NUVB Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Nuvation Bio (NUVB) stake by 15% in Q2 2026, selling an estimated $14.8K and leaving 16,780 shares worth $95.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2218.

Tower Research Capital (TRC) first reported a position in NUVB in Q4 2020 and has held it in 23 quarters since. The position peaked at $153K in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Tower Research Capital (TRC) held 16,780 shares of Nuvation Bio worth $95.3K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,029 Nuvation Bio shares in Q2 2026, an estimated $14.8K.
  • Nuvation Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2218 holding.
  • Tower Research Capital (TRC) first reported a position in Nuvation Bio in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Nuvation Bio position peaked at $153K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.